Dupilumab, an anti-IL-4Ra therapy, exhibits a higher remission rate, with about 30% of patients reaching remission [27], owing to its effective targeting of the IL-4/IL-13 pathway, crucial for type 2 inflammation-driven asthma [28]. This evidence concerns the gene IL13 and asthma.